GSK plc

GSK plc (NYSE: GSK) is a global biopharmaceutical company operating through two main segments: Commercial Operations and Research & Development. It focuses on developing cancer treatments for conditions such as ovarian cancer, endometrial cancer, and multiple myeloma. The company’s product portfolio includes vaccines, specialty medicines, and general medicines, addressing unmet medical needs in respiratory and inflammatory diseases.

Recent Business and Financial Updates

• Solid Financial Performance in 2024: GSK reported robust financial results for 2024, with total sales reaching £31.4 billion, a 3% increase at actual exchange rates (AER), and a 7% increase at constant exchange rates (CER). The company’s specialty medicines segment saw impressive growth, with sales up 19%, driven by a 13% rise in HIV sales, a remarkable 98% increase in oncology, and a 13% growth in respiratory/immunology and other products. However, vaccine sales declined by 4%, primarily due to a 51% drop in sales of Arexvy, despite a 1% increase in Shingrix sales.
• Core Profit Growth Despite Litigation Charge: While total operating profit declined by 33%, largely attributed to a £1.8 billion charge related to the settlement of the Zantac litigation, GSK’s core operating profit increased by 11%. This growth was fueled by strong performance in specialty medicines and a disciplined approach to increased investment in research and development (R&D). The company also saw a 10% rise in core earnings per share (EPS), reflecting a solid foundation for continued profitability.
• Impressive Cash Flow and Shareholder Returns: GSK demonstrated strong operational efficiency, generating £8 billion in cash from operations and achieving free cash flow of £3 billion. In line with its commitment to returning value to shareholders, the company declared a Q4 2024 dividend of 16p per share, bringing the total dividend for the year to 61p per share. GSK also announced a £2 billion share buyback program to be executed over the next 18 months, reinforcing its commitment to enhancing shareholder returns.
• Strong R&D Progress and Pipeline Expansion: Research and development efforts continued to make significant strides in 2024, with 71 specialty medicines and vaccines now in clinical development, including 19 in phase III/registration. The company achieved 13 positive phase III readouts in key therapeutic areas, including respiratory, immunology, oncology, and infectious diseases. Furthermore, GSK pursued strategic acquisitions and research alliances, including the acquisition of IDRx, Inc. (focused on GI cancers), Aiolos Bio (asthma), and a collaboration with Flagship Pioneering (respiratory and immunology).
• Guidance for 2025: Looking ahead to 2025, GSK expects continued growth, with turnover anticipated to increase by 3% to 5% and core operating profit and core EPS projected to grow by 6% to 8%, including the expected benefits from the share buyback program. Specialty medicines are expected to drive growth, with a low double-digit increase in turnover, while vaccines are forecast to decline slightly. General medicines are expected to remain stable.
• Long-term Growth Outlook and 2031 Sales Target: GSK has revised its long-term growth outlook, now anticipating sales exceeding £40 billion by 2031, up from the previous estimate of £38 billion. This adjustment reflects the progress made in its late-stage pipeline, including the anticipated contributions from products like Blenrep, as well as additional launch opportunities in the 2025–2031 period. The company continues to expect strong growth throughout the 2021–2026 period, with sales growing at a compound annual growth rate (CAGR) of more than 7% and core operating profit increasing by over 11%. GSK remains confident in its ability to drive future growth through its early-stage pipeline and strategic business development initiatives.

Technical Observation (on the daily chart):

GSK plc has been in a downtrend but is showing signs of stabilization and potential reversal. The price is above the 21-day MA (34.02) and the 50-day MA (34.09), with RSI at 55.37, serving as dynamic short to medium-term support levels. This signals a moderate bullish momentum. Key resistance is at 37.98–40.76, and support at 30.31. A breakout above resistance could confirm an uptrend, while failure to hold support may lead to further downside.

GSK delivered a strong financial performance in 2024, with robust growth in specialty medicines, solid core profit increases, and impressive cash flow generation. Despite a litigation charge, the company’s strategic focus on R&D, with numerous advancements in its pipeline, positions it for continued success. GSK’s strong balance sheet, commitment to shareholder returns through dividends and a GBP 2 billion share buyback, and an optimistic 2025 outlook with a revised long-term sales target of GBP 40 billion by 2031, highlight its strong growth potential and ongoing innovation across key therapeutic areas. 

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Buy’ rating has been given to GSK plc (NYSE: GSK) at the closing market price of USD 34.84 as of February 04,2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is February 04,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.